These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33116490)

  • 21. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.
    Kumar S; Shen J; Burgess DJ
    J Control Release; 2014 Oct; 192():95-102. PubMed ID: 25009979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique.
    Wu W; Zu Y; Wang L; Wang L; Wang H; Li Y; Wu M; Zhao X; Fu Y
    Drug Deliv; 2017 Nov; 24(1):1713-1720. PubMed ID: 29115900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
    Allam AN; Hamdallah SI; Abdallah OY
    Int J Nanomedicine; 2017; 12():4733-4745. PubMed ID: 28740381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement.
    Gera S; Talluri S; Rangaraj N; Sampathi S
    AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
    Wang Y; Han X; Wang J; Wang Y
    Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by d-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfate.
    Qiao H; Chen L; Rui T; Wang J; Chen T; Fu T; Li J; Di L
    Int J Nanomedicine; 2017; 12():1033-1046. PubMed ID: 28223797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and Evaluation of Diosgenin Nanocrystals to Improve Oral Bioavailability.
    Liu CZ; Chang JH; Zhang L; Xue HF; Liu XG; Liu P; Fu Q
    AAPS PharmSciTech; 2017 Aug; 18(6):2067-2076. PubMed ID: 27995466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
    Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
    Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs.
    Khalid N; Sarfraz M; Arafat M; Akhtar M; Löbenberg R; Ur Rehman N
    J Pharm Pharm Sci; 2018; 21(1):398-408. PubMed ID: 30365396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
    Sun W; Ni R; Zhang X; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ; Gajera BY; Dave RH
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
    Sun R; Shen C; Shafique S; Mustapha O; Hussain T; Khan IU; Mehmood Y; Anwer K; Shahzad Y; Yousaf AM
    Int J Nanomedicine; 2020; 15():705-715. PubMed ID: 32099359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.
    Liu D; Xu H; Tian B; Yuan K; Pan H; Ma S; Yang X; Pan W
    AAPS PharmSciTech; 2012 Mar; 13(1):295-304. PubMed ID: 22246736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size.
    Pi J; Liu Z; Wang H; Gu X; Wang S; Zhang B; Luan H; Zhu Z
    Curr Drug Deliv; 2016; 13(8):1358-1366. PubMed ID: 26953239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
    Parmar K; Shah J
    Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.